Post Operative Atrial Fibrillation: Alleviation by Calcium Chloride Injection Into Cardiac Ganglionic Plexus During Coronary Artery Bypass Grafting.
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
This study hypothesize that injecting calcium chloride (CaCl2) into the major atrial ganglionated plexus (GPs) during on pump Coronary artery bypass graft (CABG) can reduce the incidence of Post operative Atrial fibrillation in the first 7 days after surgery.The study is designed to be prospective interventional study two armed RCT for on pump CABG patient. The intervention arm will be injected with Calcium chloride in the four major atrial ganglionic plexus The control arm will be injected with sodium chloride to determine the effect of Calcium chloride on Post CABG Atrial fibrillation
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 74
Healthy Volunteers: f
View:
• 1\) Patients more than 18 years old 2 ) patients undergoing On pump CABG
Locations
Other Locations
Egypt
Ain shams university
RECRUITING
Cairo
Contact Information
Primary
Nadine O Elgarhi, pharmacist
nadinesadek2013@hotmail.com
01144249948
Backup
Ahmed A Foad, Assoc prof
01114567874
Time Frame
Start Date: 2024-03-14
Estimated Completion Date: 2025-04
Participants
Target number of participants: 100
Treatments
Experimental: Calcium chloride injection in ganglionated plexis for Atrial Fibrillation alleviation post CABG
The Patients in the intervention arm will be injected with Calcium chloride in the 4 major atrial ganglionated plexis after the by pass is completed.
Placebo_comparator: patients who will receive their regular standard of care without calcium chloride injection
A group of patients who will undergo Coronary artery bypass graft surgery will be injected with normal saline in the ganglionic Plexus during Coronary artery bypass graft to act as a comparator to determine if calcium chloride injection alleviate Atrial fibrillation post surgery
Related Therapeutic Areas
Sponsors
Leads: Helwan University